Journal article

Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial

Edward R Smith, Fei Fei M Pan, Tim D Hewitson, Nigel D Toussaint, Stephen G Holt

KIDNEY INTERNATIONAL REPORTS | ELSEVIER SCIENCE INC | Published : 2020

Abstract

Introduction: Calciprotein particles (CPPs) are potentially modifiable mediators of phosphate toxicity in patients with kidney disease. We compared the effects of calcium carbonate (CC) and the non-calcium-based phosphate binder sevelamer on CPP levels in patients undergoing hemodialysis (HD). We hypothesized that treatment with sevelamer would achieve greater reductions in amorphous calcium phosphate-containing CPP (CPP-1) and hydroxyapatite-containing CPP (CPP-2) owing to reduced calcium loading and anti-inflammatory pleiotropic effects. Methods: We conducted an open-label, randomized controlled trial (RCT) in which 31 stable prevalent HD patients were allocated to receive either sevelamer..

View full abstract

Grants

Funding Acknowledgements

Study funding and investigational drug was kindly provided by Sanofi-Aventis (Singapore) Pte Ltd. The investigators are solely responsible for the design, conduct, collection, analysis, and interpretation of the data, writing of the report, and the decision to submit for publication, with no input from Sanofi-Aventis (Singapore) Pte Ltd.